Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 22, 2026 11:00 ET | Source: MoonLake Immunotherapeutics AG

MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results

In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% of patients achieving ASAS40 by Week 12Consistently,...
October 27, 2025 20:04 ET | Source: DiCello Levitt LLP

SHAREHOLDER ALERT: DiCello Levitt LLP Announces That A Shareholder Class Action Has Been Filed Against MoonLake Immunotherapeutics (NASDAQ: MLTX)

DiCello Levitt LLP: MoonLake investors wishing to serve as lead plaintiff have until December 15, 2025, to petition the Court.
October 20, 2025 08:53 ET | Source: Bleichmar Fonti & Auld

MLTX SECURITIES NEWS: MoonLake Immunotherapeutics (NASDAQ: MLTX) Faces Securities Fraud Allegations after Stock Drops 90% -- Contact BFA Law by December 15 Class Action Deadline

MoonLake Immunotherapeutics investors that lost money on their investment are encouraged to contact BFA Law about their rights.
October 15, 2025 11:18 ET | Source: Block & Leviton LLP

SHAREHOLDER ALERT: MoonLake Immunotherapeutics Sued For Securities Fraud by Block & Leviton LLP; December 15 Deadline To Seek To Serve As Lead Plaintiff

Block & Leviton filed a class action lawsuit today against MoonLake Immunotherapeutics (Nasdaq: MLTX). Investors should contact the firm by December 15.
September 28, 2025 12:04 ET | Source: MoonLake Immunotherapeutics AG

MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab

VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (HS) and the first Phase 3...
June 10, 2024 08:00 ET | Source: MoonLake Immunotherapeutics AG

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis Builds upon the positive...
March 10, 2024 12:00 ET | Source: MoonLake Immunotherapeutics AG

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day Positive 24-week data from...
March 04, 2024 08:00 ET | Source: MoonLake Immunotherapeutics AG

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024 ZUG, Switzerland, March 4, 2024 – MoonLake...
February 29, 2024 08:00 ET | Source: MoonLake Immunotherapeutics AG

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10A successful year including the announcements of positive data...
February 26, 2024 08:00 ET | Source: MoonLake Immunotherapeutics AG

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS) Clarified...